RNA Medicine Rewrites the Rules: Zorevunersen Becomes First Therapy to Show Disease Modification in Dravet Syndrome

For the families of children with Dravet syndrome, the past two decades have been defined by a painful paradox: scientists understood the genetic cause of the disease with remarkable precision, yet that knowledge translated into almost nothing therapeutically useful. That changed today. In the March 5 issue of The New England Journal of Medicine, Stoke Therapeutics and Biogen published data showing that zorevunersen, an investigational antisense oligonucleotide, can do something no treatment has ever done before in this disease: modify its course.

The publication is not a minor incremental update. It represents the first clinical evidence that a therapy can alter the underlying trajectory of Dravet syndrome, a severe developmental and epileptic encephalopathy caused by mutations in the SCN1A gene. The data, drawn from two completed Phase 1/2a studies and their open-label extensions, show that patients treated with zorevunersen experienced substantial and durable reductions in seizure frequency alongside meaningful improvements in cognition, communication, motor skills, and quality of life. Crucially, these gains did not plateau. They continued deepening through three additional years of treatment in the extension studies.

What Makes This Different From Everything That Came Before

To appreciate the significance of this publication, it helps to understand what Dravet syndrome actually does to a child. Seizures typically begin in the first year of life, often triggered by fever. Around age two, neurodevelopment plateaus. From that point forward, children fall progressively further behind their peers in language, motor function, social skills, and daily living. The disease does not simply cause seizures; it derails the entire developmental arc of a child's life.

Existing treatments, including the recently approved trofinetide, address symptoms. They can reduce seizure burden at the margins, but they do not touch the underlying biology. Zorevunersen takes a fundamentally different approach. Using Stoke's proprietary TANGO platform, the drug is designed as an antisense oligonucleotide that targets the unaffected, wild-type copy of the SCN1A gene, coaxing it to produce more functional NaV1.1 protein. Rather than compensating for the broken gene, it amplifies what remains working. The result, at least in these early studies, is a restoration of protein levels toward those seen in asymptomatic carriers of the mutation.

The distinction between symptomatic relief and disease modification matters enormously in rare pediatric neurology. A drug that reduces seizures by 30 percent is valuable. A drug that also improves a child's ability to dress independently, communicate with their parents, and engage socially is transformative. The NEJM data suggest zorevunersen may be doing both.

The Clinical Evidence and Its Limitations

Eighty-one patients received at least one dose of zorevunersen across the Phase 1/2a studies. The most substantial seizure reductions were observed in patients who received the highest initial dose of 70 mg. Improvements across the Vineland Adaptive Behavior Scales, which measure communication, daily living skills, socialization, and motor function, continued through the open-label extension period. The overall clinical status and quality of life measures moved in the same direction.

The safety picture is broadly encouraging but not without nuance. The most common treatment-related adverse event was cerebrospinal fluid protein elevation, observed in 44 percent of patients in the open-label extension studies. No related clinical manifestations have been reported, though one patient discontinued treatment due to elevated CSF protein levels. The drug is administered intrathecally, meaning directly into the spinal canal, which adds procedural complexity and limits the population that can practically access it.

These are Phase 1/2a data. They are open-label, meaning neither patients nor investigators were blinded to treatment. The patient population was highly refractory, which makes the improvements more striking but also limits direct comparisons to broader Dravet populations. The Phase 3 EMPEROR study, currently enrolling approximately 150 patients in a double-blind, sham-controlled design, will provide the definitive test. Topline data are expected in mid-2027.

The Broader Implications for RNA Medicine

Zorevunersen's mechanism sits within a rapidly maturing class of therapeutics. Antisense oligonucleotides have already demonstrated their power in spinal muscular atrophy, where nusinersen transformed outcomes for a disease once considered uniformly fatal in infancy. The TANGO approach, which targets splicing to upregulate expression from a functional gene copy, extends this logic to haploinsufficiency disorders, conditions where one working copy of a gene is insufficient to maintain normal function.

Dravet syndrome is the lead indication, but the platform's logic applies to a wide range of neurological conditions caused by similar mechanisms. If the Phase 3 data confirm what the early studies suggest, zorevunersen would validate not just a single drug but an entire approach to treating genetic epilepsies and potentially other haploinsufficiency disorders of the central nervous system.

The Biogen partnership adds commercial and scientific weight to the program. Stoke retains rights in the United States, Canada, and Mexico; Biogen holds commercialization rights for the rest of the world. For Biogen, which has navigated a difficult period following the controversies surrounding its Alzheimer's program, a successful rare disease launch in pediatric neurology would represent a meaningful strategic reorientation.

What Families Are Actually Waiting For

Mary Anne Meskis, CEO of the Dravet Syndrome Foundation, whose son has lived with the disease for more than 25 years, put the stakes plainly in the announcement accompanying the publication. A treatment that could help someone dress independently or communicate more clearly with their parents, she said, would profoundly change the cadence and quality of everyday life. That framing is worth holding onto as the field awaits Phase 3 results.

The NEJM publication is a milestone, but it is not an approval. The EMPEROR study must succeed. The regulatory pathway, which includes FDA Breakthrough Therapy Designation and Rare Pediatric Disease designation, is favorable, but pivotal trials in rare pediatric diseases have a history of disappointing even when early data looked compelling. The sham-controlled design of EMPEROR, which uses intrathecal sham procedures to maintain blinding, is methodologically rigorous and will provide a cleaner read than the open-label studies published today.

Still, the publication of these data in the world's most prestigious medical journal, with three years of follow-up showing continued improvement rather than waning effect, is a genuinely significant moment. For a disease that has resisted every attempt at disease modification since its genetic cause was identified in 1998, the arrival of a therapy that may finally be changing the underlying biology represents something the field has been waiting a long time to see.